Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Sells $36,725.00 in Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 6,500 shares of the stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Voyager Therapeutics Trading Down 2.9 %

VYGR stock opened at $5.74 on Friday. The firm has a 50-day moving average of $6.31 and a two-hundred day moving average of $6.99. Voyager Therapeutics, Inc. has a 12 month low of $5.19 and a 12 month high of $11.72. The company has a market cap of $313.55 million, a price-to-earnings ratio of 8.08 and a beta of 0.90.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.29. The firm had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter last year, the firm earned ($0.59) earnings per share. As a group, equities analysts forecast that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new stake in shares of Voyager Therapeutics in the second quarter valued at about $85,000. Bank of New York Mellon Corp boosted its holdings in Voyager Therapeutics by 17.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 294,420 shares of the company’s stock valued at $2,329,000 after purchasing an additional 44,289 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in shares of Voyager Therapeutics by 36.8% in the 2nd quarter. Commonwealth Equity Services LLC now owns 77,905 shares of the company’s stock valued at $616,000 after buying an additional 20,950 shares during the period. Rhumbline Advisers increased its holdings in shares of Voyager Therapeutics by 56.0% during the 2nd quarter. Rhumbline Advisers now owns 72,461 shares of the company’s stock worth $573,000 after buying an additional 26,014 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in shares of Voyager Therapeutics by 14.5% during the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after buying an additional 1,630 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Analyst Upgrades and Downgrades

VYGR has been the topic of a number of recent analyst reports. Leerink Partners assumed coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Wedbush assumed coverage on shares of Voyager Therapeutics in a report on Friday, November 29th. They issued an “outperform” rating and a $11.00 price target for the company. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Citigroup started coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They set a “buy” rating and a $12.00 target price for the company. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $17.00.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.